Form 4: Calidi Biotherapeutics Director Schoeneck Reports Stock Grant

Director James A. Schoeneck reports acquisition of 28,207 shares of Calidi Biotherapeutics common stock through a grant of restricted stock units.

Summary

• On March 29, 2024, James A. Schoeneck, a director of Calidi Biotherapeutics, Inc., acquired 28,207 shares of common stock.
• This acquisition was through a grant of restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan.
• The RSUs fully vested on the grant date.
• Following the transaction, Schoeneck beneficially owns 992,094 shares of Calidi Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock transactions. No inherent positive or negative implications.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.
• The RSUs fully vested on the grant date.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where equity compensation is frequently used.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment as it aligns director interests with company performance.

Key Dates